<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CALCITRIOL <img border="0" src="../images/pr.gif"/></span><br/>(kal-si-trye'ole)<br/><span class="topboxtradename">Calcijex, </span><span class="topboxtradename">Rocaltrol<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">vitamin d analog</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.25 mcg, 0.5 mcg tablets; 1 mcg/mL oral solution; 1 mcg/mL, 2 mcg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic form of an active metabolite of ergocalciferol (vitamin D<sub>2</sub>). In the liver, cholecalciferol (vitamin D<sub>3</sub>) and ergocalciferol (vitamin D<sub>2</sub>) are enzymatically metabolized to calcifediol, an activated form of vitamin D<sub>3</sub>. Calcifediol is biodegraded in the kidney to calcitriol, the most potent form of vitamin D<sub>3</sub>. Patients with nonfunctioning kidneys are unable to synthesize sufficient calcitriol and therefore must receive it pharmacologically.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>By promoting intestinal absorption and renal retention of calcium, calcitriol elevates serum calcium levels, decreases elevated
         blood levels of phosphate and parathyroid hormone, and decreases subperiosteal bone resorption and mineralization defects
         in some patients.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Management of hypocalcemia in patients undergoing chronic renal dialysis and in patients with hypoparathyroidism or pseudohypoparathyroidism.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Selected patients with vitamin Ddependent rickets, familial hypophosphatemia (vitamin Dresistant rickets); management
         of hypocalcemia in premature infants.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypercalcemia or vitamin D toxicity; pregnancy (category C), lactation. Safe use in children not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hyperphosphatemia, patients receiving digitalis glycosides.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypocalcemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.25 mcg/d, may be increased by 0.25 mcg/d q48wk for dialysis patients or q24wk for hypoparathyroid patients if
               necessary <span class="rdroute">IV</span> 0.5 mcg 3 times/wk at the end of dialysis, may need up to 3 mcg 3 times/wk<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> On hemodialysis: 0.252 mcg/d. <span class="rdroute">IV</span> 0.010.05 mcg/kg 3 times/wk Renal failure without dialysis: <span class="rdroute">PO</span> 0.0140.041 mcg/kg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Oral dose can be taken either with food or milk or on an empty stomach. Discuss with physician.</li>
<li>When given for hypoparathyroidism, the dose is given in the morning.</li>
<li>Capsules should be protected from heat, light, and moisture. Store in tightly closed container.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give IV push over 3060 s.  
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Muscle or bone pain. <span class="typehead">CV:</span> Palpitation. <span class="typehead">GI:</span> Anorexia, nausea, vomiting, dry mouth, thirst, constipation, abdominal cramps, metallic taste. <span class="typehead">Metabolic:</span> Vitamin D intoxication, hypercalcemia, hypercalciuria, hyperphosphatemia. <span class="typehead">CNS:</span> Headache, weakness. <span class="typehead">Special Senses:</span> Blurred vision, photophobia. <span class="typehead">Urogenital:</span> Increased urination. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">thiazide diuretics</span> may cause hypercalcemia; calcifediol-induced hypercalcemia may precipitate digitalis arrhythmias in patients receiving <span class="classification">digitalis glycosides</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 26 h. <span class="typehead">Peak:</span> 1012 h. <span class="typehead">Duration:</span> 35 d. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted mainly in feces. <span class="typehead">Half-Life:</span> 36 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Determine baseline and periodic levels of serum calcium, phosphorus, magnesium, alkaline phosphatase, creatinine;
            measure urinary calcium and phosphorus levels q24h.
         </li>
<li>Effectiveness of therapy depends on an adequate daily intake of calcium and phosphate. The physician may prescribe a calcium
            supplement on an as-needed basis.
         </li>
<li>Monitor for hypercalcemia (see Signs &amp; Symptoms, Appendix F). During dosage adjustment period, monitor serum calcium levels
            particularly twice weekly to avoid hypercalcemia.
         </li>
<li>If hypercalcemia develops, withhold calcitriol and calcium supplements and notify physician. Drugs may be reinitiated when
            serum calcium returns to normal.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Discontinue the drug if experiencing any symptoms of hypercalcemia (see Appendix F) and contact physician.</li>
<li>Do not use any other source of vitamin D during therapy, since calcitriol is the most potent form of vitamin D<sub>3</sub>. This will avoid the possibility of hypercalcemia.
         </li>
<li>Consult physician before taking an OTC medication. (Many products contain calcium, vitamin D, phosphates, or magnesium, which
            can increase adverse effects of calcitriol.)
         </li>
<li>Maintain an adequate daily fluid intake unless you have kidney problems, in which case consult your physician about fluids.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>